Dermatitis Asthma Atopic Disease The INTEGUMENT-2 trial included patients 6 years of age and older with mild to moderate atopic dermatitis involving at least 3% body surface area. Positive topline ...
Arcutis Biotherapeutics (ARQT) announced the enrollment of the last subject in the INTEGUMENT-INFANT Phase 2 open-label clinical study, which is evaluating the safety and tolerability of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback